detail The Thank discuss in steps cytisinicline On Jaime. the call, the ORCA-X clinical second Xb our development highlights you, more quarter today's has the been and of the review I next results. trial will program. Phase in results
that second-quarter our update John financial will results. Following provide an on discussion,
cytisinicline our drug Phase trial development As provided powerful announced dose Xb X in optimization into as June, Phase data expectations our future and ORCA-X program. to inform the performance an exceeded trial from insights and antismoking
a dosing quick upon currently was selection patients. needed Europe Eastern ORCA-X marketed treated XX explore Achieve already in it over was doses placebo. and dose cytisinicline million improve a As efficacy conducted? study comparing Why other whether Central and to schedules safety of might reminder, and the versus product the which has
using both was All smoking XX dosing, marketed for ORCA-X evaluated three-times-daily in subjects primary milligram currently In of X.X of the the we The end endpoint treated trial, cytisinicline titration X days. were the schedule. treatment. at a daily schedule and declining TID, or new reduction and doses
a X importantly, at the end the cessation from trials. On Phase enrolled smokers average, abstinence record four-week starting years, treat, by approval US total approximately opinion prolonged eight. to for entering nicotine were their in continuous smokers for specific patients were a eight and ORCA-X been on rate is study, have at These to relevant was XX endpoint the leaders centers abstinence very four-week XX; cigarettes of XXX in week US. considered the subjects the rates to in difficult of time. given FDA of ORCA-X day. XX the subjects smoking the treatment age endpoint secondary be around The Most to across addiction key smoking
this benefit which will discuss profile, by efficacy Given shortly. were extremely they cytisinicline's impressed we
were abstinence four-week weeks week the treatment were In the trial, measure with eight-week measuring expired provided of face-to-face period. four, for at eight either to subjects support the course behavioral was was or and of reporting. measured XX activity, through which then were the of study. Smoking cytisinicline carbon CO, study. from abstinence the assessments treated end placebo full end over days with a of which verified Continuous weekly Abstinence was accurate smoking was ensure or the biochemical by measured monoxide, five the
elements safety assessed key adherence treatment. to Additional were and that included
in show regardless summary, schedule, the treatment abstinence rates placebo. number the or that ORCA-X improvements cytisinicline experienced reduction in on cigarettes results subjects to the of regimen, and XX-day In compared of smoked significant both dose
reported. reported. with consistent adherence no subjects strong to a smoked, And CO was to placebo. comparison expired observed. number the treatment and Additionally, adverse decline There greater of receiving of cytisinicline serious had in events study profile favorable was cigarettes were safety A
FDA we beginning to evaluating milligram the going feedback support a XX% the with X considerations on and the schedule focus Phase future future administration X simplified designed demonstrated milligram, commercial impressive future advance less with was treatment in I will most results arm three-times-daily endpoint an in schedule. This arm in and were three-times-daily trials. trials treatment week to into the milligram, most of XX% trials. The and provide optimal The quit clarity dose three-times-daily observed relevant forward, like that the dose to ORCA-X conjunction the highly at on a than trial X impressive significant utilize placebo, X data, X.XXX. approval. results now p-value abstinence three-times-daily FDA those result. rates, The milligram, rate would dose four with on for for to was X compared previous
in a p-value compared weeks four-week X.XXX. five addition, abstinence to of for placebo, was cytisinicline only In X again milligram, continuous X% measured the XX% highly from significant through arm three-times-daily for eight with
the self-reported reduction was in and reduction reduction in of of carbon in This XX% cigarettes objective in three-times-daily by reduction provided the smoked. cigarettes similar monoxide. highest was X level study verification Additionally, the XX% the in a CO milligram, smoked XX% arm, matched the
the In had XX% could in placebo XX% of indicating cigarettes not group measured. by but a smoked. self-reported significant group verified be smoked of actual reduction had contrast, decline cigarettes number CO, underreporting placebo CO The a in the only
analysis, used this Using had very smoking the is outcome trials by frequently treatment four. of all in arms additional week odds an at of strong Finally, cessation success we treatment across end a measure ratios.
treatment X arm, odds a times milligram by to ratio smoking X.X, the likely was the the three meaning placebo. milligram, day over were to to cytisinicline quit Specifically X end of six times compared three-times-daily smokers using the more
continuous impressive three-times-daily treatment eight-week decrease abstinence in an verified four the X of an efficacy provided had among milligram, and of measurements, the odds and arms, perspective, rates ratio biochemically largest both X.X. also the In from highest smoking summary, arm the the
three-times-daily subjects the of safety out most abnormal or occurring XX, of of now insomnia. and excellent The three only X X% with events profile and reflected constipation, placebo X% experience adverse for arm to commonly in and this compared adherence. to a Turning the rate at drug. all prior safety was safety were trial reported milligram, treatment cytisinicline dreams the In
both. X to Clearly infections milligram, for tract respectively, compared and higher effect arm three-times-daily nausea Additionally, side rates were X% of the XX%, upper for on reported subjects and the XX% respiratory placebo. placebo
events show real smokers cytisinicline to continues for of events benefits cessation side to issue effects little effects deterrent pooled to around safety no are might to available across potential maintain consider safety a exceeded The adverse profile were medication. The and with When cytisinicline arms, currently clean no willingness treatments all smoking likely in treatment-limiting. smokers' major that prescription compliance be side to observed XX%.
ORCA-X level clinical impressive, an The which is for adherence smoking adherence of visit. were trial was diaries by medication X by issue. closely drug trials all of has treatment milligram, each cytisinicline Our direct trial high historic virtually the arms experience been given the in treatment monitored at unheard cessation specifically, In and other subjects XX.X%, monitoring across compliance was adherence where three-times-daily of arm of. packaging to
extremely show with expectations rates schedule. yet was and This robust abstinence safety, efficacy, adherence. and trial level the smoking the abstinence, was successful The because three-times-daily milligram designed and excellent to specifically showed conclusion, is important in In it our did. not of this trial exceeded ORCA-X dose, the significant dosing simplified X
we family they Now themselves given that stated you member. XXX a powerful. statistics perhaps completed In numbers but a post-study showing to more smokers performed XX% was recommend have from that cytisinicline and the survey lots cytisinicline how or patients received well would ORCA-X, are friend it treatment, of feedback in who by
subjects: wanted the short opportunity XX weeks." treated in "I you after taken back." life research And from this a are quit become appreciate another cytisinicline I I years. study giving for here And one: better to direct such was to and couldn't "It study. quotes some my smoke-free awesome. Thank years, have worked for
"Staff Feel A friends. one: was further great. like
or ORCA-X to September for from forward good trying. at will cytisinicline trial Finally to on XX. data Society Research European Thank XX SRNT, multiple oral upcoming and data quit We much." in Two the after sharing meeting held years on for presentations additional occur & during look XX-plus meeting. Tobacco, being times you Nicotine so Oslo featuring the
like I'd from updates couple brief a to share Now quarter. the other of
MTD, continue including We NDA advance tolerated or dose, our supportive maximum to study. the studies
requirement FDA this inform It way. to a the previously in an study issues Phase recommended overdose setting. exceeds of potential trial outside dosing safety in As not a smoker event mentioned, clinical any our in is to evaluate intended fulfills X dose the situation an
dose. cytisinicline evaluated date, evidence been has milligrams of will of without single single toxicity, To continue to dose the and milligram a of study XX up a XX
ethics we to dosing in report the which recommence we You third to results may study get quarter. higher final remember for that and the had have, expect doses, and approval week next now pause to
this next National million the nonclinical development which the the year. Additionally with expected has to NIH quarter, they of Institutes be collaboration collaboration, to research to extended efforts are completed we program. strategic studies of $X additional announced Under have or the we extended our committing will Health, The extremely nearly of research supportive conduct NIH. that of provide been cytisinicline,
That concludes quarter. our updates the for second
our the to based in meeting with we ORCA-X results. hand, the data of turn coming will and May principle, design on trial key trial scheduling X confirm results protocols focus want plans FDA the now in Phase for trials. At FDA outcome are ORCA-X Phase our we will the XXXX, agreed the modify number months. to ORCA-X priorities the but finalizing was in review a of and discussions We clinical X With for our to future
importantly, continue will progressing potential studies We and carcinogenicity. the in discussions we supportive development commercialization nonclinical with execute to such and US are both an as internationally. partners long-term additional And NDA
hand John financial over our now to will results. I to discuss the call
